Natera, Inc. (NASDAQ:NTRA) Insider Sells $86,527.06 in Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 929 shares of Natera stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $93.14, for a total transaction of $86,527.06. Following the sale, the insider now owns 110,748 shares in the company, valued at $10,315,068.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Natera Price Performance

NASDAQ NTRA opened at $96.98 on Friday. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $98.82. The company has a market cap of $11.86 billion, a PE ratio of -25.59 and a beta of 1.38. The stock’s 50-day moving average price is $90.56 and its two-hundred day moving average price is $69.29.

Natera (NASDAQ:NTRA) last released its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.09. The business had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. On average, analysts predict that Natera, Inc. will post -2.35 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on NTRA shares. The Goldman Sachs Group boosted their price target on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, April 15th. Canaccord Genuity Group upped their target price on Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. Piper Sandler increased their price target on Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Raymond James downgraded Natera from a “strong-buy” rating to an “outperform” rating and boosted their price objective for the stock from $68.00 to $85.00 in a research note on Tuesday, February 20th. Finally, Stephens reaffirmed an “overweight” rating and set a $78.00 target price on shares of Natera in a research note on Tuesday, January 30th. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $86.40.

Institutional Trading of Natera

Large investors have recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Natera in the fourth quarter worth $83,970,000. American Century Companies Inc. grew its stake in Natera by 115.7% during the 3rd quarter. American Century Companies Inc. now owns 1,654,303 shares of the medical research company’s stock valued at $73,203,000 after acquiring an additional 887,409 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Natera by 52.0% in the 3rd quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company’s stock valued at $111,930,000 after purchasing an additional 865,404 shares during the period. Perceptive Advisors LLC increased its holdings in shares of Natera by 289.7% in the 4th quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock valued at $53,258,000 after purchasing an additional 632,047 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Natera by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock worth $687,280,000 after purchasing an additional 588,147 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.